Amgen (NASDAQ:AMGN) and GENFIT S A/ADR (NASDAQ:GNFT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Dividends

Amgen pays an annual dividend of $5.80 per share and has a dividend yield of 3.3%. GENFIT S A/ADR does not pay a dividend. Amgen pays out 40.3% of its earnings in the form of a dividend. Amgen has raised its dividend for 8 consecutive years.

Profitability

This table compares Amgen and GENFIT S A/ADR’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amgen 34.00% 71.02% 14.07%
GENFIT S A/ADR N/A N/A N/A

Insider & Institutional Ownership

77.3% of Amgen shares are owned by institutional investors. Comparatively, 15.3% of GENFIT S A/ADR shares are owned by institutional investors. 0.3% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Amgen and GENFIT S A/ADR’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Amgen $23.75 billion 4.51 $8.39 billion $14.40 12.19
GENFIT S A/ADR N/A N/A N/A N/A N/A

Amgen has higher revenue and earnings than GENFIT S A/ADR.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Amgen and GENFIT S A/ADR, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen 0 8 10 0 2.56
GENFIT S A/ADR 0 0 5 0 3.00

Amgen currently has a consensus price target of $207.00, suggesting a potential upside of 17.88%. GENFIT S A/ADR has a consensus price target of $52.62, suggesting a potential upside of 149.85%. Given GENFIT S A/ADR’s stronger consensus rating and higher possible upside, analysts plainly believe GENFIT S A/ADR is more favorable than Amgen.

Summary

Amgen beats GENFIT S A/ADR on 9 of the 12 factors compared between the two stocks.

Amgen Company Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. It also markets other products in various markets, including Kyprolis, Nplate, Vectibix, Repatha, NEUPOGEN, Parsabiv, Blincyto, Aimovig, Imlygic, Corlanor, Kanjintitm, and Amgevitatm. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaborative agreements with Novartis; UCB; Bayer HealthCare Pharmaceuticals Inc.; and DaVita Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

GENFIT S A/ADR Company Profile

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic test for the identification of patients with NASH; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.